Abstract

Boromycin is a boron-containing polyether macrolide antibiotic isolated from Streptomyces antibioticus. It was shown to be active against Gram positive bacteria and to act as an ionophore for potassium ions. The antibiotic is ineffective against Gram negative bacteria where the outer membrane appears to block access of the molecule to the cytoplasmic membrane. Here we asked whether boromycin is active against Mycobacterium tuberculosis which, similar to Gram negative bacteria, possesses an outer membrane. The results show that boromycin is a potent inhibitor of mycobacterial growth (MIC50 = 80 nM) with strong bactericidal activity against growing and non-growing drug tolerant persister bacilli. Exposure to boromycin resulted in a rapid loss of membrane potential, reduction of the intracellular ATP level and leakage of cytoplasmic protein. Consistent with boromycin acting as a potassium ionophore, addition of KCl to the medium blocked its antimycobacterial activity. In contrast to the potent antimycobacterial activities of the polyether macrolide, its cytotoxicity and haemolytic activity were low (CC50 = 30 μM, HC50 = 40 μM) with a selectivity index of more than 300. Spontaneous resistant mutants could not be isolated suggesting a mutation frequency of less than 10-9/CFU. Taken together, the results suggests that targeting mycobacterial transmembrane ion gradients may be an attractive chemotherapeutic intervention level to kill otherwise drug tolerant persister bacilli, and to slow down the development of genetic antibiotic resistance.

Highlights

  • Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB), remains the biggest bacterial killer with 1.3 million deaths per year (Zumla et al, 2014)

  • We first determined whether boromycin shows antimycobacterial activity or whether the outer membrane of mycobacteria would, similar to the outer membrane in Gram negative bacteria, cause intrinsic resistance to the antibiotic

  • Boromycin is a polyether macrolide antibiotic with selective activity against Gram positive bacteria where it acts as ionophore for potassium ions

Read more

Summary

Introduction

Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB), remains the biggest bacterial killer with 1.3 million deaths per year (Zumla et al, 2014). Emergence of genetic drug resistance and persistence of infection despite extensive chemotherapy represent two major issues in current TB treatment regimens (Barry et al, 2009; Gengenbacher and Kaufmann, 2012). TB drugs, like most antibiotics, target specific macromolecules. Antibiotic resistance arises mainly from mutations in target genes (Cohen et al, 2014). Genetic resistance occurs readily in patients due to non-compliance to lengthy (6–24 months) multi-drug regimens and spatio-temporal pockets of monotherapy (Prideaux et al, 2015). Persistence of infection is thought to be due to various types of metabolically quiescent non-growing drug tolerant bacteria. Several culture models have been developed to study

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call